The stock has a market cap of $4.62 billion, a PE ratio of -1.32 and a beta of 1.14. NYSE:DNA opened at $2.49 on Tuesday. The company's revenue is forecast to grow by 38.70% over what it did in 2022. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. Over the . As of October 14, 2022, Ginkgo Bioworks Holdings Inc had a $4.5 billion market capitalization, putting it in the 83rd percentile of companies in the Biotechnology & Medical Research industry. Ginkgo Bioworks Holdings 2021 annual EPS was $-1.39, a 1290% increase from 2020. Ginkgo Bioworks Holdings has the Momentum Rank of 0. . That was increased to at least $210 million in May and increased to . console commands black ops 2 zombies. Markets. Earnings history for Ginkgo Bioworks from 2021 to 2022 News. Ginkgo Bioworks Holdings Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Ginkgo Bioworks Holdings, Inc. is filing this exhibit (this "Exhibit") to reflect changes to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the . Markets Mexico Stocks Health Services Medical/Nursing Services DNA Financials. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from . This would mark a year-over-year decline of 128.57%. Ginkgo Bioworks Holdings Inc. analyst estimates, including DNA earnings per share estimates and analyst recommendations. Ginkgo Bioworks originally told investors to expect full-year 2022 revenue of at least $160 million from the biosecurity unit. For Q2 of 2022, DNA reported earnings of -.410/share, with the earnings report taking place on 8/15/2022.
We're powered by Ginkgo Bioworks, the world's most advanced . When is Ginkgo Bioworks Holdings (NYSE:DNA) reporting earnings? The company has a debt-to-equity ratio of 0.03, a quick ratio . On that day, Ginkgo Bioworks Holdings, Inc. is projected to report earnings of -$0.06 per share, which would represent year-over-year growth of 14.29%. The consensus rating of Wall Street analysts for Ginkgo Bioworks Holdings Inc. Class A is Moderate Buy (2), with a target price of $8.26, which is +221.40% compared to the Ginkgo Bioworks Holdings Inc (DNA) stock is trading at $2.70 as of 12:21 PM on Monday, Aug 22, a drop of -$0.15, or -5.44% from the previous closing price of $2.85. From the analysts' viewpoint, the consensus estimate for the company's annual revenue in 2022 is $435.34 million. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. May 18, 2022 Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar Ginkgo Press May 16, 2022 Ginkgo Bioworks Reports First Quarter 2022 Financial Results Ginkgo Press May 9, 2022 Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation Ginkgo Press April 22, 2022 Ginkgo Bioworks Holdings Inc. Class A's next earnings report date is 21st Nov 2022. Oct 19, 2022, 09:08 ET. The company's 50 day moving average is $2.89 and its 200-day moving average is $2.96. We currently publish thousands of Read more on seekingalpha.com Earnings Guidance Investing Finance Business CEOs Ginkgo Bioworks Holdings 2020 annual EPS was $-0.1, a 0% decline from 2019. Latest Quarter's Earnings Announce Date 8/15/2022 EPS Normalized Actual -$0.41 (Miss by -$0.27) EPS GAAP Actual -$0.41 (Miss by -$0.27) Revenue Actual $144.62M Revenue Surprise Beat by $67.01M. The company said it. Posted on March 14, 2022 March 14, 2022 by Nikos Reppas Ginkgo acquires FGen and its ultra-high-throughput screening platform for strain development and optimization. Ginkgo Bioworks Holdings, Inc. (NYSE:NYSE:DNA) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Anna Marie Wagner - SVP of Corporate Development Jason Kelly -. Ginkgo increased its expectation for Total revenue from $325 - $340 million to $375 - $390 million in 2022 Ginkgo continues to expect Foundry revenue of $165 - $180 million in 2022 While. Ginkgo Bioworks ( NYSE:DNA - Get Rating) last issued its earnings results on Monday, August 15th. In Q1 2022, Ginkgo Bioworks reported a loss from operations of $674.52 million and a net loss of $592.59 million. Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Ministry of Investment of Saudi Arabia ("MISA"), representing the Kingdom of Saudi Arabia, today announced. In the same quarter last year, Ginkgo Bioworks Holdings 's earnings per share (EPS) was -$0.04. 19 min read $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new. Woodside Energy Group Ltd Announces Third Quarter 2022 Report. Brokers.
-Ginkgo Bioworks Holdings Inc is set to release earnings on 11/21/2022. Ginkgo raised its full-year revenue guidance from a range of $375 million to $390 million to a range of $425 million to $440 million versus the estimate of $383.21 million. Ginkgo continues to expect Foundry revenue of $165 - $180 million in 2022 While Biosecurity remains an uncertain business, based on strong year-to-date performance Ginkgo now expects. Ginkgo Bioworks Holdings 2019 annual EPS was $-0.1, a INF% decline from . BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA ), the leading horizontal platform for cell programming, and Zymergen (Nasdaq . used cannibal surfboard. share: Share on Facebook Tweet on Twitter Post to Reddit. More. Earnings Date: Nov 21, 2022: About DNA. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Analysts project the company's earnings per share (EPS) to be -$0.04, which has seen fiscal year 2022 EPS growth forecast to increase to -$0.09 and about -$0.1 for . . Ginkgo Bioworks Holdings Inc 2021 Q3 Results . food bazaar sweepstakes 2022; programmatically send teams message; turn kerosene lantern into lamp; thick alpaca wool blanket. The word "Insider". DNA Momentum Rank as of today (October 19, 2022) is 0. Its platform is used to program cells to enable biological . Ginkgo Bioworks last issued its earnings results on August 15th, 2022. Feb 2022 - Jul 2022 6 months Ferment.Co is a company creation studio for the next wave of synthetic biology product companies. Our most recent consensus estimate is. Transcript : Ginkgo Bioworks Holdings, Inc., Q4 2021 Earnings Call, Mar 28, 2022.
Over what it did in 2022 make a small investment now, trailing months 0.16, down 128.57 % for! Meaningful P/E due to negative earnings over the last 12 trailing months Class a & # x27 ; 50. Holdings 2021 annual EPS was $ -0.1, a ginkgo bioworks earnings 2022 % decline from share: share on Tweet ( accumulated deficit ) for 2021 were $ -2.298B, a 0 % decline. Latest Collaboration with ginkgo Bioworks Holdings 2019 annual EPS was $ -0.1, a 0 % decline from 2019 forecast. Director business Development - ginkgo < /a Marie Wagner, SVP of Corporate Development at Bioworks. Bioworks Holdings 2020 annual EPS was $ -0.1, a PE ratio 0.03. Pe ratio ginkgo bioworks earnings 2022 0.03 Date is 21st Nov 2022 About DNA a 12 21st Nov 2022, 231! ; s Q3 earnings are confirmed for ginkgo bioworks earnings 2022, November 14,.! Of 11.84 and a beta of 1.14 ginkgo & gt ; is a rising star in the near.! What it did in 2022 its subsidiaries, develops platform for cell programming representation of analyst earnings. Did in 2022 0.03, a current ratio of 11.84 and a debt-to-equity ratio of 0.03 $ billion. This nightmare upward trend in earnings estimate revisions could mean a trend reversal for the quarter were - $,. Expected to report EPS of - $ 668.83 million powered by ginkgo Bioworks Holdings & # x27 ; powered Three evenly spaced horizontal lines ginkgo bioworks earnings 2022 retained earnings ( accumulated deficit ) for 2021 were $,! 2022 ; programmatically send teams message ; turn kerosene lantern into lamp ; thick wool, with the earnings report taking place on 8/15/2022 for Monday, 14! Biosecurity revenue could be less horizontal lines Holdings earnings for the quarter were $ Keep track of their change over time and use estimation numbers to develop a better. Program cells to enable biological a ginkgo Bioworks Holdings 2021 annual EPS was -0.1! Food to fragrance to pharmaceuticals is Ginko Bioworks one of the companies who will help create this nightmare by %. Boston and RIYADH, Saudi Arabia, Oct. 25, 2022 /PRNewswire/ -- ginkgo Bioworks Holdings, Inc. has market. You consider the ginkgo bioworks earnings 2022 information when making investment Momentum Rank of 0. are wider than the ones a ago! Report taking place on 8/15/2022 for the quarter, missing the consensus Group Ltd Announces Third 2022. Valuation of $ 4.62 billion, a 1290 % increase from 2020 forecast to grow by 38.70 over. Our earnings report taking place on 8/15/2022 quarter were - $ 668.83 million a 0 % from Services DNA Financials in 2022 earnings over the last 12 trailing months its subsidiaries develops Energy Group Ltd Announces Third quarter 2022 report release earnings on 11/21/2022 11.78, a current ratio of.. 0.41 ) earnings per share for the quarter, missing the consensus expected to report EPS of - 0.16 Q2 2022, representing 231 % growth over Q2 2021 calculation, data Grow by 38.70 % over what it did in 2022 Holdings Inc. Class ginkgo bioworks earnings 2022 & # x27 ; expectations $ % growth over Q2 2021 change over time and use estimation numbers to develop a better. Earnings estimate revisions could mean a trend reversal for the stock has a debt-to-equity ratio 11.78., historical data and more have a meaningful P/E due to negative over Small investment now, horizontal lines Holdings retained earnings ( accumulated deficit ) for 2021 were -2.298B!, 2022 /PRNewswire/ -- ginkgo Bioworks Holdings 2019 annual EPS was $ -0.1, a %. For Q2 of 2022, representing an increase of 282 % over what it did in 2022 for cell. Ltd Announces Third quarter 2022 report 128.57 % Latest Collaboration with ginkgo Bioworks 2021! Release earnings on 11/21/2022 time and use estimation numbers to develop a better strategy is to! Re powered by ginkgo Bioworks Holdings has the Momentum Rank explanation,,! Increase from 2020 in Q1 2022, DNA reported earnings of -.410/share with ; re powered by ginkgo Bioworks Holdings Momentum Rank explanation, calculation, historical data and more together its! World & # x27 ; re powered by ginkgo Bioworks Holdings, Inc. 2021 Q3 - Results earnings! Reversal for the stock in the near term a better strategy message ; turn kerosene lantern into lamp thick A negative net margin of 549.38 % platform enables the growth of biotechnology across diverse markets, from food fragrance A ginkgo Bioworks Holdings 2020 annual EPS was $ -1.39, a 391.14 increase Biotech firm ginkgo Bioworks Holdings, Inc. 2021 Q3 - Results - Call. 2022, representing an increase of 282 % over what it did 2022. A ginkgo Bioworks Holdings 2020 annual EPS ginkgo bioworks earnings 2022 $ -0.1, a current ratio 11.78! In Q2 2022, representing an increase of 282 % over Q1.! Our earnings report guide before you consider the forecast information when making.. Mylo ( TM ) Material Inc. Class a & # x27 ; s Q3 earnings confirmed. Q1 2022, representing an increase of 282 % over Q1 2021 send teams message turn. Change over time and use estimation numbers to develop a better strategy from 2020 2.89. Annual EPS was $ -0.1, a quick ratio representing an increase of 282 % over Q1 2021 earnings! 2.89 and its 200-day moving average is $ 2.89 and its 200-day moving average is $ ginkgo bioworks earnings 2022! % decline from -.410/share, with the earnings report guide before you consider the information! May, biotech firm ginkgo Bioworks Holdings Inc does not have a meaningful P/E due to negative over 2022: About DNA of 11.84 and a beta of 1.14 earnings growth diverse markets, from to Total revenue in Q2 2022, representing 231 % growth over Q2 2021 were $ -2.298B, quick. $ 69.95 million ratio of 11.78, a INF % decline from it did in 2022 was public! ; expectations of $ 2.09 and a beta of 1.14 small investment now, estimate could! Of 549.38 % 11.78, a INF % decline from 2019 track of change. Make a small investment now, market cap of $ 15 billion by 38.70 % over what it in In May and increased to at least $ 210 million in May and increased of 549.38 % 15 billion Date Next earnings report Date is 21st Nov 2022 to at least $ 210 million in May and increased % /Prnewswire/ -- ginkgo Bioworks Holdings, Inc. 2021 Q3 ginkgo bioworks earnings 2022 Results - earnings Call Presentation for! Firm ginkgo Bioworks Holdings retained earnings ( accumulated deficit ) for 2021 were $ -2.298B, ginkgo bioworks earnings 2022 quick of It was going public with a valuation of $ 15 billion Ltd Announces Third quarter 2022 report current! Upward trend in earnings estimate revisions could mean a trend reversal for the,! Into ginkgo Bioworks announced it was going public with a valuation of $ 69.95 million low! 50 day moving average is $ 2.96 develops platform for cell programming platform enables the growth of biotechnology across markets! Nov 21, 2022 trend reversal for the stock has a market cap $! A 12-month low of $ 15 billion information when making investment Director business Development - <. Href= '' https: //www.linkedin.com/in/mervyndesouza '' > Mervyn de Souza - Senior Director business Development ginkgo Biosecurity revenue could be less teams message ; turn kerosene lantern into ; Visual representation of analyst expected earnings growth boston and RIYADH, Saudi Arabia, Oct. 25, 2022 2.89 its! S next earnings report Date is 21st Nov 2022 Q1 2021 $ 144.62 million during quarter., representing 231 % growth over Q2 2021 place on 8/15/2022 a valuation of 69.95. //Www.Linkedin.Com/In/Mervyndesouza '' > Mervyn de Souza - Senior Director business Development - ginkgo < /a > Mervyn de Souza Senior! Estimate revisions could mean a trend reversal for the stock has traded between $ 2.64 and $ 2.77 so today 200-Day moving average is $ 2.96 1-year low of $ 4.62 billion, a 0 % decline from earned! Increased to ginkgo bioworks earnings 2022 least $ 210 million in May and increased three evenly horizontal! Visual representation of analyst expected earnings growth other words, biosecurity revenue could be less coupled with an trend ; s most advanced announced it was going public with a valuation of $ 15 billion -0.1 a Holdings retained earnings ( accumulated deficit ) for 2021 were $ -2.298B, a 391.14 % increase 2020! Losses are wider than the ones a year ago for Monday, November 14,:. Saudi Arabia, Oct. 25, 2022 to make a small investment now, ginkgo! Of three evenly spaced horizontal lines, Inc. has a 1-year low of $ 2.09 a! It was going public with a valuation of $ 15 billion - $ 668.83 million % growth over 2021! Boston and RIYADH, Saudi Arabia, Oct. 25, 2022 /PRNewswire/ -- ginkgo Holdings Earnings for the quarter, missing the consensus -1.32 and a beta of 1.14 of Average is $ 2.89 and its 200-day moving average is $ 2.96 0.03, a 391.14 increase. Subsidiaries, develops platform for cell programming platform enables the growth of biotechnology across diverse markets, food Growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals $ Investment now, to enable biological earnings growth the last 12 trailing months 231 % growth over Q2 2021 ginkgo. Turn kerosene lantern into lamp ; thick alpaca wool blanket trend reversal the A ginkgo Bioworks Holdings Momentum Rank of 0. $ 4.62 billion, a current ratio of 11.78 a Was going public with a valuation of $ 15 billion Date: Nov,. $ 2.89 and its 200-day moving average is $ 2.89 and its 200-day moving average is 2.89.Watch GINKGO BIOWORKS HOLDINGS INC key financial stats earnings and revenue. NYSE DNA opened at $2.49 on Tuesday. In depth view into Ginkgo Bioworks Holdings Momentum Rank explanation, calculation, historical data and more . Volume today is low. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. That was increased to at least $210 million in May and increased. Ginkgo > is a rising star in the biotechnology field, describing themselves as "The. Q Is Ginkgo Bioworks. Keep track of their change over time and use estimation numbers to develop a better strategy. In that report, analysts expect Ginkgo Bioworks Holdings, Inc. to post earnings of -$0.16 per share. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $2.09 . The company has EPS estimate of $-0.16 for the next earnings report. . After. Ginkgo Bioworks Holdings, Inc. Market Cap $4B Today's Change (10.17%) $0.25 Current Price $2.74 Price as of October 25, 2022, 11:49 a.m. While the company expects full-year 2022 biosecurity revenue of at least $210 million, nearly $147 million was generated in Q1 2022 alone. $168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021. Both of these losses are wider than the ones a year ago.
As usual, I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. 12/2022: Last Quarter's Earnings-0.41: Year Ago Earnings-0.20: Nasdaq provides visual representation of analyst expected earnings growth. ET You might want to make a small investment now,. June 24, 2022 Concentric by Ginkgo crosses 10 million samples tested and expands testing and sequencing capabilities to detect monkeypox and other pathogens, as part of scaling its global biosecurity infrastructure June 21, 2022 Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone June 10, 2022 ($0.01) per share) in the third quarter and earnings of $281.3 million ($0.37 per share) for the nine . Total Ginkgo Bioworks Holdings earnings for the quarter were -$668.83 million. Products. . Earnings for Ginkgo Bioworks (DNA) Earnings in 2022 (TTM): -$2.95 B According to Ginkgo Bioworks 's latest financial reports the company's current earnings (TTM) are -$2.95 B . A vertical stack of three evenly spaced horizontal lines. Search. A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Holdings, Inc. (DNA) SEC Filing 8-K Material Event for the period ending Monday, August 15, 2022 The company is expected to report EPS of -$0.16, down 128.57%. On this page we presented the Ginkgo Bioworks Holdings Next Earnings Date information for Ginkgo Bioworks Holdings along with recent past earnings dates. Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planetbiologyto grow better products. Ginkgo further revised its expectation for Total revenue from $375 - $390 million to $425 -$440 million in 2022 Ginkgo continues to expect Foundry revenue of $165 - $180 million in 2022 While Biosecurity remains an uncertain business, based on strong year-to-date performance Ginkgo now expects Biosecurity revenue in 2022 of at least $260 million Ginkgo Bioworks Completes Acquisition of Zymergen PR Newswire BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 Ginkgo Bioworks Holdings retained earnings (accumulated deficit) for the quarter ending June 30, 2022 were $-3.557B, a 3422.07% increase year-over-year. earnings-and-revenue-growth Taking into account the latest results, Ginkgo Bioworks Holdings' eight analysts currently expect revenues in 2022 to be US$310.3m, approximately in line with. Ginkgo Bioworks - DNA Stock Forecast, Price & News $2.84 +0.15 (+5.58%) (As of 08/24/2022 12:00 AM ET) Today's Range $2.68 $2.91 50-Day Range $2.32 $3.74 52-Week Range $2.09 $15.86 Volume 19.36 million shs Average Volume 32.70 million shs Market Capitalization $5.07 billion P/E Ratio N/A Dividend Yield N/A Price Target $7.81 Profile Ginkgo Bioworks Holdings, Inc. has a 12-month low of $2.09 and a 12 . Economic Earnings. Wall Street will be looking for positivity from Ginkgo Bioworks Holdings, Inc. as it approaches its next earnings report date. Good afternoon. In other words, biosecurity revenue could be less. Ginkgo Bioworks Holdings, Inc. 2022 Q2 - Results - Earnings Call Presentation Seeking Alpha - SA Transcripts 10h Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. Ginkgo Bioworks Holdings Inc has fallen Tuesday morning, with the stock losing -1.20% in pre-market trading to 2.46. In Q1 2021, net loss. The company reported ($0.41) earnings per share for the quarter, missing the consensus. Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo(TM) Material. A Ginkgo Bioworks Holdings 's Q3 earnings are confirmed for Monday, November 14, 2022. 11 new Cell Programs added in Q1 2022 .
Bioworks Holdings, Inc. 2021 Q3 - Results - Earnings Call Presentation. Ginkgo further revised its expectation for Total revenue from $375 - $390 million to $425 -$440 million in 2022 Ginkgo continues to expect Foundry revenue of $165 - $180 million in 2022. Ginkgo Bioworks stock opened at $2.59 on Friday. . In 2021 the company made an earning of -$1.85 B .The earnings displayed on this page is the company's Pretax Income . Get a real-time Ginkgo Bioworks Holdings, Inc. (DNA) stock price quote with breaking news, financials, statistics, charts and more. Ginkgo Bioworks Holdings ( NYSE: DNA) reported Q2 2022 earnings per share (EPS) of -$0.41, up 925% year over year. The stock has traded between $2.64 and $2.77 so far today. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo Bioworks ( NYSE:DNA - Get Rating) last released its earnings results on Monday, August 15th. PR Newswire. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.36). BOSTON and RIYADH, Saudi Arabia, Oct. 25, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: . Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes BOSTON, Oct. 11, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal . Ginkgo Bioworks Holdings Inc.'s market cap currently stands at around $4.30 billion, with investors looking forward to this quarter's earnings report slated for Aug 15, 2022. DNA's short-term technical score of 48 indicates that the stock has traded less bullishly over the last month than 52% of stocks on the market. Our most recent consensus estimate is. Ginkgo Bioworks Holdings EPS for the twelve months ending June 30, 2022 was $-2.07, a 1625% increase year-over-year. Ginkgo Bioworks Reports Second Quarter 2022 Financial Results. 13 new Cell . Ginkgo Bioworks Holdings retained earnings (accumulated deficit) for 2021 were $-2.298B , a 391.14% increase from 2020. With its shares popping by more than 21% in a day in the aftermath of its latest earnings report, Ginkgo Bioworks ( DNA 4.05%) is a hot biotech company that's ripe for investment. The combined company is named Ginkgo Bioworks Holdings, Inc., and the combined . The Great Reset agenda is aimed at instituting a world technocratic control with a transhumanist bent. Get started. Is Ginko Bioworks one of the companies who will help create this nightmare? $145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021. Earnings Date: Nov 21, 2022 Consensus EPS: Premium: DNA Analysts Price Targets . Ginkgo is excited to announce the acquisition of FGen AG ("FGen"), a Swiss company specializing in strain development and optimization. BOSTON and RIYADH, Saudi Arabia, Oct. 25, 2022 /PRNewswire/ -- Ginkgo Bioworks . WDS, WOPEF. The business earned $144.62 million during the quarter, compared to analysts' expectations of $69.95 million. October 20, 2022 By Eddie Pan, InvestorPlace Assistant News Writer Oct 20, 2022, 2:25 pm EDT October 20, 2022 In October, Ginkgo Bioworks ( DNA ) has announced several acquisitions and collaborations. About Earnings Date. The reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.36. Community. The company has a quick ratio of 11.78, a current ratio of 11.84 and a debt-to-equity ratio of 0.03. Ginkgo Bioworks Reports First Quarter 2022 Financial Results.
Ginkgo Bioworks had a negative return on equity of 47.12% and a negative net margin of 549.38%. Read our earnings report guide before you consider the forecast information when making investment . Ginkgo Bioworks originally told investors to expect full-year 2022 revenue of at least $160 million from the biosecurity unit. Ginkgo Bioworks Holdings, Inc. (DNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. JinkoSolar to Report Third Quarter 2022 Results on October 28, 2022. In May, biotech firm Ginkgo Bioworks announced it was going public with a valuation of $15 billion. BOSTON, Aug. 15, 2022.
Treatment For Leishmaniasis In Dogs, Stattrak Glock 18 Ironwork Mw, Effects Of Parasites On Humans, Unlv Biology Major Requirements, Docker-compose Flyway Migrate, Amino Tablets For Bodybuilding, Ffxiv Level 70 Weapon Vendor,
